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Background: EC145 is a novel folate-receptor targeted agent con-
sisting of a folate molecule linked to a vinca alkaloid. EC20 is a 
technetium-labeled folate that assesses the presence of folate recep-
tors (FR) in vivo. The objective of this study was to determine the 
activity of EC145 in patients with chemotherapy refractory lung 
adenocarcinoma, whose tumors expressed the FR as determined by 
EC20 imaging.
Methods: Patients with advanced adenocarcinoma of the lung, 
Eastern Cooperative Oncology Group performance status 0 to 2, 
normal organ function, those who had progressed after at least two 
prior cytotoxic regimens, and with EC 20 uptake in at least one index 
lesion were eligible. The primary objective of the study was the abil-
ity to receive four or more cycles of therapy.
Results: Sixty patients were screened and 43 patients were enrolled. 
Eleven patients (26%) received more than four cycles (95% confi-
dence interval [CI] 14%, 41%), and one patient had partial response 
(response rate (RR) = 2.3%, 95% CI 0%, 12%). Patients in whom 
all target tumor lesions expressed FR by EC 20 scans had a trend 
toward superior results in terms of clinical benefit response (50% 
versus 14.3 %; p = 0.10) and survival (47.2 weeks versus 14.9 weeks 
[HR = 0.539, p = 0.101]) compared with those in whom at least one 
but not all target lesions were positive for FR (FR+).
Conclusion: EC145 demonstrated clinical activity with a good toxic-
ity profile in this population. Uniform uptake of EC20 may predict 
activity of EC145 and be useful for prospective selection of patients 
in future trials.
Key Words: EC145, EC20, Folate receptor, Non–small-cell lung 
cancer.
(J Thorac Oncol. 2012;7: 1618–1621)
EC145, a conjugate of folate and the vinca alkaloid desacetylvinblastine hydrazide is an experimental agent, 
which targets malignancies that overexpress the folate recep-
tor (FR).1 Tissue array analysis using immunohistochemical 
techniques has identified the FR as being expressed on more 
than 75% of non–small-cell lung cancers. Early clinical evi-
dence suggests that EC145 is well tolerated, without many 
of the side effects observed in vinca alkaloids.2 As the FR is 
recycled every 12 to 24 hours, repetitive dosing of the agent 
is indicated.3
Folate transfers one-carbon chemical units from donor 
to acceptor molecules in a variety of critical biosynthetic 
processes. Folate gains entry into the mammalian cells, via two 
distinct transport systems: the reduced folate carrier system, the 
primary method of folate entry, and the FR system.4,5 Although 
FR glycoprotein is expressed in a minority of normal tissues, 
it is expressed at high levels on the surface of some epithelial 
tumors, including adenocarcinoma of the lung and ovarian 
cancer.,6,7 Steric inhibition largely prohibits FR-targeted 
conjugates such as EC145 from entering cells via the reduced 
folate carrier pathway. These findings led to the hypothesis 
that FR-targeted conjugates could be used to deliver imaging 
agents to identify FR-expressing tumor cells then, ultimately, 
to deliver therapeutic agents in an FR-targeted manner.8
METHODS
Eligibility
Patients aged 18 years and above with an Eastern 
Cooperative Oncology Group performance status of 0 to 2 
with a diagnosis of advanced, progressive, adenocarcinoma 
of the lung, who had previously received more than two 
 cytotoxic-containing chemotherapeutic regimens (+/− epider-
mal growth factor receptor tyrosine kinase inhibitors) were 
eligible for screening.
To be eligible for the study, at least 4 weeks should have 
elapsed from prior therapy and patients should have recovered 
from associated acute toxicities. Patients were also eligible if 
they had measurable disease and more than one target tumor 
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lesions, which expressed FR by EC20 scans, identified as EC20 
positive (see below). Adequate organ function was required and 
was defined as an absolute neutrophil count of 1.5 × 109/L or 
more, platelets of 100 × 109/L or more, and hemoglobin of 9 g/
dL or more, total bilirubin less than 1.5 mg/dL, serum creatinine 
of 1.5 × (upper limit of normal) ULN or lesser, or creatinine 
clearance of 60 mL/min/1.73m or more2 for patients with serum 
creatinine × levels above 1.5 × ULN. Women of childbearing 
potential were eligible if they had a negative serum pregnancy 
test. Written informed consent was obtained from all patients. 
The Institutional Review Boards of each respective institution 
approved the trial before the first enrollment at the institution.
99mTc-EC20 Imaging
Eligible patients received one intravenous injection of 
0.5 mg folic acid (to decrease background uptake),9 followed 
within 1 to 3 minutes by a 1- to 2-ml injection of 0.1 mg of 
EC20 labeled with 20 to 25 mCi of technetium 99m. Patients 
then underwent planar imaging (mid-thigh to head, posterior, 
and anterior images) 1 to 2 hours after injection of 99m Tc-EC20. 
Single-photon emission computed tomography (CT) images 
of the region(s) known to contain the target lesions(s) were 
obtained immediately thereafter. Target lesions were selected 
by the radiologist according to Response Evaluation Criteria 
In Solid Tumors 1.0. Nuclear medicine physicians then 
visually assessed 99mTc-EC20 uptake for each target lesion 
and classified the uptake as either positive (marked or mild 
uptake) or negative (no uptake). Mild uptake was defined as 
uptake that was slightly above that of the background, whereas 
marked uptake was defined as significantly increased over the 
background. Target lesions less than 15 mm were considered 
nonevaluable unless the reader marked them as having 99mTc-
EC20 uptake. Target lesions that were located in organs of 
high background uptake (e.g., liver, spleen, bladder, or kid-
ney) were also considered nonevaluable.
Treatment
Treatment with EC145 began 7 to 21 days after the 
patients had undergone 99m Tc-EC20 imaging, Figure 2. There 
was an induction phase (cycles 1, 2) during which patients 
received a bolus intravenous injection (or through an ambula-
tory pump) of 1.0 mg of EC145, daily × 5 days, for 3 weeks, 
followed by 1 week off. During the maintenance phase (cycles 
3+), patients received EC145 2.5 mg three times a week, on 
weeks 1 and 3 of a 4-week cycle. Patients could receive up to a 
total of eight cycles of therapy, and those who exhibited radio-
graphic evidence of continued tumor shrinkage at the end of 
eight cycles were allowed to continue in the study until they 
exhibited two sequential CT scans with stable disease (SD). 
CT scanning for tumor assessment was conducted every 8 
weeks. Toxicity was evaluated every 4 weeks using Common 
Toxicity Criteria for Adverse Events version 3.0.
Statistical Objectives
The primary objective was to determine the clinical 
benefit response, defined as the ability to receive more than 
four cycles (i.e., months) of therapy. This endpoint would 
indicate that patients have both responded (in terms of either 
SD or radiographic response) and tolerated therapy well. 
This endpoint relates directly to the therapy in question and 
is not contaminated by subsequent treatments. The Southwest 
Oncology Group has determined that a similar endpoint (in 
that study, defined as stability at 8 weeks) predicts survival.10 
A two-stage Minimax design was used with alpha = 0.05 and 
beta = 0.15. In stage 1, more than four of 17 patients were 
required to have clinical benefit to proceed to stage 2. In stage 
2 the target clinical benefit response was eight of 20 patients. 
Attainment of a clinical benefit ratio higher than 40% was the 
primary endpoint. A secondary objective was to determine 
whether the intensity or uniformity of FR expression on EC20 
scans correlated with outcome.
RESULTS
Sixty patients were screened, of whom 43 were enrolled 
and received at least one dose of EC145. The demographics of 
the population are listed in Table 1. The patients were heavily 
pretreated with 30 of 43 patients (70%) having received 
three or more prior chemotherapy regimens. The 43 treated 
patients received a mean of 2.9 cycles and a median of two 
cycles of therapy (range, 0–12 cycles) of EC145. EC145 
was well tolerated (Table 2). There were no drug-related 
grade 4 toxicities reported. The most common drug-related 
adverse events were fatigue (37%) and constipation in (33%), 
primarily grade 1 or 2 in severity. Peripheral neuropathy was 
reported in 9%, with only 2% being grade 3. Most patients 
FIGURE 1. EC145. Folate (module 1) acts as a targeting 
moiety to deliver a therapeutically active molecule (module 
4), identified here as drug; however, module 4 could also be 
an imaging agent, hapten or other chemical entity, depend-
ing on the desired endpoint or function. Modules 1 and 4 
are separated by a spacer (module 2) and cleavable bond 
(module 3). The spacer may be used to confer desirable 
chemical characteristics (hydrophilicity, -phobicity, acid stabil-
ity, lability, etc.) to the overall conjugate, and module 3 is 
formulated as either a cleavable or a stable bond depending, 
again, on the ultimate function of module 4. In the case of 
drug delivery (i.e., the desired release of module 4), once the 
conjugate is internalized via folate- receptor–mediated endo-
cytosis, the bond located in module 3 hydrolyzes to release 
the warhead (module 4) molecule. In the case where module 
4 is an imaging agent (e.g., 99mTc) and release is not desired, 
module 3 could contain a noncleavable bond. In this case, 
the entire conjugate is tightly bound (Kd ≈10–10 M) via folate 
to the receptor, and remains bound throughout the entire 
recycling process. Functionally then, the folate-99mTc conju-
gate acts to mark or identify FR-expressing cells by remaining 
bound to the receptor.
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(25 of 43, 58%) discontinued therapy because of progressive 
disease. The other reasons for discontinuation included 
physician decision (7 patients), death (7 patients), withdrawal 
of consent (1 patient), and completed protocol-specified 
maximum number of cycles (3 patients).
The primary objective of the trial was not met, in that 
a clinical benefit response of 26% (95% CI 14%, 41%) was 
obtained. Fifteen patients had disease control at 8 weeks 
(35%, 95% CI 21%, 51%), the Southwest Oncology Group 
definition of clinical benefit and a partial response (response 
rate [RR] = 2.3%, 95% CI 0%, 12%) was observed, indicating 
activity of the agent.
A substantial fraction of patients (11 of 43) had base-
line scans that were obtained more than 28 days before enroll-
ment, and one patient did not have a baseline scan. In addition, 
one patient was later found to not have adenocarcinoma of 
the lung and one patient had inadequate organ function. Thus, 
Table 1. Demographics
Characteristic N (43)
Age, median (range) yrs 62 (36–82)
Male/Female 27/16
Performance status
 0–1 36
 2 7
Number of prior cytotoxic regimens
 2 13
 3 12
 4 7
 >4 11
Smoking status
 Smoker or ex-smoker 34
 Nonsmoker 8
Table 2. Treatment-emergent drug-related adverse events 
in ≥ 5% of patients (N = 43)
All Grades Grade 3/4 Grade 3 Grade 4
At least one drug-related 
adverse event
36 (83.7) 6 (14.0)
Blood and Lymphatic 
System Disorders
 Anemia 6 (14.0) 0 (0.0) 0 (0.0) 0 (0.0)
Gastrointestinal disorders
 Constipation 14 (32.6) 0 (0.0) 0 (0.0) 0 (0.0)
General disorders
 Fatigue 16 (37.2) 2 (4.7) 2 (4.7) 0 (0.0)
Metabolism and nutrition 
disorders
 Anorexia 5 (11.6) 1 (2.3) 1 (2.3) 0 (0.0)
Nervous system disorders
 Dizziness 3 (7.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Neuropathy peripheral 4 (9.3) 1 (2.3) 1 (2.3) 0 (0.0)
Psychiatric disorders
 Insomnia 3 (7.0) 0 (0.0) 0 (0.0) 0 (0.0)
Vascular disorders
 Hypotension 4 (9.3) 0 (0.0) 0 (0.0) 0 (0.0)
FIGURE 2.  Study schema. CT, computed tomography; IV, intravenous.
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an analysis of the remaining 29 patients was also performed. 
For these patients (n = 29) clinical benefit response (ability 
to receive ≥ 4 cycles of EC145) was seen in 9 patients (31 %, 
95% CI 15%, 51%) and median progression-free survival was 
7.4 weeks (95% CI 7.1, 15.1) with a median overall survival of 
32.1 weeks (95% CI 9.3, 62.3). Further exploratory analysis 
demonstrated that for patients in this group, who had disease 
in which all target tumor lesions demonstrated EC20 uptake 
(FR++, n=14), there was a superior clinical benefit response 
compared with those who had at least one but not all target 
lesions positive for FR (FR+, n = 14) (50% versus 14.3 %; 
p = 0.10, Fisher’s exact test). An overall survival advantage 
was also noted for the FR++ patients versus the FR+ patients 
with a median of 47.2 weeks versus 14.9 weeks (hazards ratio 
[HR] = 0.539, p = 0.101, one-sided test). The median progres-
sion-free and overall survivals for the entire treated population 
were 7.4 weeks and 42.9 weeks, respectively.
DISCUSSION
The results above indicate activity of EC145 in a 
highly refractory population with advanced NSCLC. Though 
the objective of prolonged disease stability (clinical benefit 
response) was not met, 38% of the patients received more 
than two full cycles of therapy and therefore demonstrated 
SD at the first reassessment. Importantly, there was an indica-
tion that evaluation with EC20 has the potential to select for 
patients for EC145 therapy. Specifically, uptake of EC20 in 
all target tumor lesions as opposed to uptake in at least one 
but not all target tumor lesions may be a predictive marker 
for EC145 treatment. However, the current study cannot 
exclude the possibility that EC20 uptake represents a posi-
tive prognostic marker. This study supports further develop-
ment of EC145 and other FR-targeted therapeutics for the 
treatment of adenocarcinoma of the lung. The noninvasive 
EC20 agent offers the potential to rationally select patients 
for this approach without the need for a biopsy. A randomized 
phase II trial evaluating the activity of EC145 versus EC145 + 
docetaxel versus docetaxel alone in FR++ tumors has been 
activated. This study will require central assessment of EC20 
scans.
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